Robinhood Opens The Door To U.S. Cannabis Stocks

Retail investors may have just gained a new pathway into some of the largest U.S. cannabis companies.

Shares of major multi-state operators, including Trulieve (OTC: TCNNF), Curaleaf (OTC: CURLF), and Green Thumb (OTC: GTBIF), recently became tradable on Robinhood after previously appearing on the platform only as non-tradable tickers, according to industry reports and company executives.

The move marks one of the clearest signs yet that parts of the mainstream retail brokerage ecosystem are becoming more comfortable with U.S. cannabis equities as federal marijuana reform discussions accelerate.

Why This Matters

For years, many retail investors faced limited access to U.S. plant-touching cannabis operators because the companies trade over-the-counter rather than on major U.S. exchanges such as the Nasdaq or the New York Stock Exchange.

Federal cannabis prohibition has historically prevented major exchange listings for companies directly involved in cannabis cultivation, manufacturing, and retail operations.

That dynamic has contributed to:

  • lower liquidity,
  • a smaller investor base,
  • reduced institutional participation,
  • and higher capital costs across the cannabis sector.

Robinhood’s decision does not change federal law, but it does increase visibility and accessibility for some of the industry’s largest operators.

Executives Are Publicly Celebrating The Move

Green Thumb Industries CEO Ben Kovler publicly acknowledged the development on social media, while Curaleaf Chairman and CEO Boris Jordan also thanked Robinhood for adding the company to the platform.

According to MJBizDaily, the addition follows earlier cannabis-related listings on Robinhood, including Glass House Brands, which became available on the platform in 2025.

The Bigger Story May Be What Comes Next

The timing is notable.

The development comes as the cannabis industry continues monitoring federal marijuana rescheduling proceedings after the U.S. government’s move to reclassify medical cannabis under Schedule III. Additional hearings are scheduled to begin later this month.

If federal reform advances further, many industry observers expect:

  • broader retail investor participation,
  • improved access to capital,
  • potential uplisting efforts,
  • and greater institutional involvement in the sector.

However, those outcomes remain speculative and depend on future regulatory decisions.

As cannabis consultant Hirsh Jain told MJBizDaily, major institutional investors still face restrictions tied to federal legality, custody requirements, and exchange-listing limitations.

Retail Access Is Expanding Before Institutional Capital Arrives

While Robinhood access alone is unlikely to transform cannabis valuations overnight, it may represent another step toward normalizing cannabis equities within mainstream financial infrastructure.

The larger question now is whether retail access is arriving ahead of a broader shift that eventually allows U.S. cannabis operators to compete for capital on the same exchanges as other consumer, healthcare, and pharmaceutical companies.

For now, investors can finally buy some of the industry’s largest operators through one of the most widely used retail brokerage apps in the United States—a development that would have seemed unlikely just a few years ago.


Image
Nicolas Jose Rodriguez
June 1, 2026 • 12:12 pm
Share: